Protara Therapeutics Inc (TARA)
$2.8
Insights on Protara Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 76.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 307.6%
Performance
- $2.76$3.00$2.80
1.43%
Downside
Day's Volatility :8.0%
Upside
6.67%
- $1.04$5.24$2.80
62.86%
Downside
52 Weeks Volatility :80.15%
Upside
46.56%
Returns
| Period | Protara Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -36.36% | 0.0% |
6 Months | 100.0% | 0.0% |
1 Year | -5.08% | 0.0% |
3 Years | -72.52% | -22.6% |
Highlights
Market Capitalization | 57.9M |
Book Value | $5.11 |
Earnings Per Share (EPS) | -3.73 |
Wall Street Target Price | 27.8 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -32.75% |
Return On Equity TTM | -55.45% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -45.4M |
Diluted Eps TTM | -3.73 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.86 |
EPS Estimate Next Year | -4.14 |
EPS Estimate Current Quarter | -0.92 |
EPS Estimate Next Quarter | -0.8 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 892.86%
Technicals Summary
Sell
Neutral
Buy
Protara Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Protara Therapeutics Inc | -3.45% | 100.0% | -5.08% | -72.52% | -90.67% |
 Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
 Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Protara Therapeutics Inc | NA | NA | NA | -3.86 | -0.55 | -0.33 | NA | 5.11 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Protara Therapeutics Inc | Buy | $57.9M | -90.67% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Institutional Holdings
Opaleye Management Inc
13.08%Vanguard Group Inc
2.08%Boxer Capital LLC
1.02%Ikarian Capital, LLC
0.98%Baker Bros Advisors LP
0.97%StemPoint Capital LP
0.82%
Company Information
protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york.
Organization | Protara Therapeutics Inc |
Employees | 26 |
CEO | Mr. Jesse Shefferman |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$2.80
-0.36%
Keyarch Acquisition Corp
$2.80
-0.36%
Connexa Sports Technologies Inc
$2.80
-0.36%
Us Value Etf
$2.80
-0.36%
First Wave Biopharma Inc
$2.80
-0.36%
Global X Msci Next Emerging
$2.80
-0.36%
Fat Projects Acquisition Corp
$2.80
-0.36%
Goal Acquisitions Corp
$2.80
-0.36%
Capital Link Global Fintech
$2.80
-0.36%